CA2861339C - Metalloenzyme inhibitor compounds - Google Patents

Metalloenzyme inhibitor compounds Download PDF

Info

Publication number
CA2861339C
CA2861339C CA2861339A CA2861339A CA2861339C CA 2861339 C CA2861339 C CA 2861339C CA 2861339 A CA2861339 A CA 2861339A CA 2861339 A CA2861339 A CA 2861339A CA 2861339 C CA2861339 C CA 2861339C
Authority
CA
Canada
Prior art keywords
compound
disease
metalloenzyme
mmol
family
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2861339A
Other languages
English (en)
French (fr)
Other versions
CA2861339A1 (en
Inventor
William J. Hoekstra
Robert J. Schotzinger
Stephen W. Rafferty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mycovia Pharmaceuticals Inc
Original Assignee
Mycovia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mycovia Pharmaceuticals Inc filed Critical Mycovia Pharmaceuticals Inc
Publication of CA2861339A1 publication Critical patent/CA2861339A1/en
Application granted granted Critical
Publication of CA2861339C publication Critical patent/CA2861339C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2861339A 2012-01-20 2013-01-18 Metalloenzyme inhibitor compounds Active CA2861339C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261589076P 2012-01-20 2012-01-20
US61/589,076 2012-01-20
PCT/US2013/022313 WO2013109998A1 (en) 2012-01-20 2013-01-18 Metalloenzyme inhibitor compounds

Publications (2)

Publication Number Publication Date
CA2861339A1 CA2861339A1 (en) 2013-07-25
CA2861339C true CA2861339C (en) 2020-08-25

Family

ID=48799718

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2861339A Active CA2861339C (en) 2012-01-20 2013-01-18 Metalloenzyme inhibitor compounds

Country Status (14)

Country Link
US (3) US10221160B2 (instruction)
EP (1) EP2804858B1 (instruction)
JP (1) JP6189865B2 (instruction)
KR (1) KR102061137B1 (instruction)
CN (1) CN104136427B (instruction)
AU (2) AU2013209516A1 (instruction)
BR (1) BR112014017751B1 (instruction)
CA (1) CA2861339C (instruction)
DK (1) DK2804858T3 (instruction)
EA (1) EA026209B1 (instruction)
ES (1) ES2774267T3 (instruction)
IN (1) IN2014DN06792A (instruction)
PL (1) PL2804858T3 (instruction)
WO (1) WO2013109998A1 (instruction)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102012015199A2 (pt) 2011-06-19 2014-05-13 Viamet Pharmaceuticals Inc Compostos inibidores de metaloenzima
WO2013109998A1 (en) * 2012-01-20 2013-07-25 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EA201691648A1 (ru) * 2014-03-19 2017-01-30 Ваймет Фармасьютикалс, Инк. Способ получения противогрибковых соединений
CA2942927A1 (en) * 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
WO2015143180A1 (en) * 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
JP2017514790A (ja) * 2014-03-19 2017-06-08 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
AU2015231226B2 (en) * 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
WO2015143188A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and proceses for their preparation
AU2015231216B2 (en) * 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
MX2016012060A (es) 2014-03-19 2017-01-19 Viamet Pharmaceuticals Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
EP3119748A4 (en) * 2014-03-19 2017-08-30 Viamet Pharmaceuticals, Inc. Antifungal compound process
US10196375B2 (en) 2014-03-19 2019-02-05 Mycovia Pharmaceuticals, Inc. Antifungal compound process
BR112017018823A2 (pt) 2015-03-19 2018-04-24 Viamet Pharmaceuticals, Inc. compostos antifúngicos e processos para a fabricação
PL3349586T3 (pl) 2015-09-18 2021-05-31 Mycovia Pharmaceuticals, Inc. Sposób wytwarzania związku przeciwgrzybiczego
CN108779094B (zh) * 2015-12-30 2021-11-16 Nqp 1598公司 金属酶抑制剂化合物
CA3046987A1 (en) 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CN109666019B (zh) * 2017-10-14 2021-04-06 朱允涛 一种氘代的氮唑醇类化合物及其制备方法和用途
CN109810049B (zh) * 2018-11-30 2021-01-15 深圳大学 一种含吡啶的化合物及其提取方法
WO2021143811A1 (zh) * 2020-01-17 2021-07-22 上海森辉医药有限公司 四氮唑类化合物的可药用盐及其结晶形式、制备方法和用途
CN116528855A (zh) * 2020-10-16 2023-08-01 米拉洛克斯有限责任公司 用于治疗癌症、阿尔茨海默病、血色沉着病和其它病症的金属酶抑制剂

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8304282D0 (en) * 1983-02-16 1983-03-23 Pfizer Ltd Antifungal agents
GB8305377D0 (en) 1983-02-25 1983-03-30 Pfizer Ltd Antifungal agents
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
GB8415889D0 (en) 1984-06-21 1984-07-25 Ici Plc Antifungal azole compounds
AU4327585A (en) 1984-06-21 1986-01-02 Imperial Chemical Industries Plc Antifungal azole compounds
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
ATE107176T1 (de) 1989-12-04 1994-07-15 Searle & Co System zur transdermalen albuterol applikation.
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
GB9121456D0 (en) * 1991-10-10 1991-11-27 Pfizer Ltd Triazole antifungal agents
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
US5358939A (en) 1992-06-25 1994-10-25 Rohm And Haas Company Fungicidal 2-aryl-2,2-disubstituted ethyl-1,2,4-triazoles
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
MY115814A (en) 1995-06-16 2003-09-30 Bayer Ip Gmbh Crop protection compositions
GB9512961D0 (en) 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
JP2000344744A (ja) * 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
CN101563045B (zh) 2006-10-18 2012-07-04 白李生物科技有限公司 用于根管充填的牙髓仪器和适于它的加热探头
WO2008064311A2 (en) 2006-11-21 2008-05-29 Viamet Pharmaceuticals, Inc. Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties
US8221057B2 (en) 2008-06-25 2012-07-17 General Electric Company Method, system and controller for establishing a wheel space temperature alarm in a turbomachine
KR20110048586A (ko) 2008-09-03 2011-05-11 바이엘 크롭사이언스 아게 특정 녹병균을 구제하기 위한 살진균성 조성물의 용도
CA2785898C (en) * 2009-12-31 2018-07-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2011133875A2 (en) * 2010-04-24 2011-10-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2011320565A1 (en) * 2010-10-28 2013-05-23 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
ES2703498T3 (es) * 2010-11-13 2019-03-11 Innocrin Pharmaceuticals Inc 1-(6,7-Bis(difluorometoxi)naftalen-2-il)-2-metil-1-(1H-1,2,3-triazol-4-il)propan-1-ol como inhibidor de CYP17 para el tratamiento de enfermedades dependientes de andrógenos como el cáncer de próstata
CA2820718A1 (en) * 2010-12-13 2012-06-21 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2721023B1 (en) * 2011-06-19 2018-08-08 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
BR102012015199A2 (pt) * 2011-06-19 2014-05-13 Viamet Pharmaceuticals Inc Compostos inibidores de metaloenzima
WO2012177725A1 (en) 2011-06-23 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2012300275A1 (en) * 2011-08-30 2014-03-06 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
ES2671387T3 (es) * 2011-12-11 2018-06-06 Viamet Pharmaceuticals (NC), Inc. Compuestos inhibidores de metaloenzimas
WO2013109998A1 (en) * 2012-01-20 2013-07-25 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
MX2014008729A (es) * 2012-01-20 2015-02-04 Viamet Pharmaceuticals Inc Compuestos inhibidores de metaloenzima.
CA2898615A1 (en) * 2013-01-28 2014-07-31 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN105431418B (zh) * 2013-06-12 2019-02-05 北卡罗来纳维亚梅特制药公司 金属酶抑制剂化合物
EP3131400A4 (en) * 2014-04-15 2017-11-29 Dow AgroSciences LLC Metalloenzyme inhibitor compounds as fungicides
JP2017513848A (ja) * 2014-04-15 2017-06-01 ダウ アグロサイエンシィズ エルエルシー 殺真菌剤としての金属酵素阻害剤化合物
EP4311577A3 (en) * 2016-12-29 2024-04-17 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds

Also Published As

Publication number Publication date
EA201491385A1 (ru) 2015-02-27
PL2804858T3 (pl) 2020-06-29
US20190169159A1 (en) 2019-06-06
EA026209B1 (ru) 2017-03-31
KR102061137B1 (ko) 2019-12-31
AU2017232080B2 (en) 2019-02-14
AU2017232080A1 (en) 2017-10-12
EP2804858A1 (en) 2014-11-26
JP2015504095A (ja) 2015-02-05
JP6189865B2 (ja) 2017-08-30
US20150004666A1 (en) 2015-01-01
BR112014017751B1 (pt) 2021-12-07
CN104136427A (zh) 2014-11-05
WO2013109998A1 (en) 2013-07-25
EP2804858B1 (en) 2019-12-25
BR112014017751A8 (pt) 2021-03-09
CN104136427B (zh) 2017-03-01
AU2013209516A1 (en) 2014-08-28
EP2804858A4 (en) 2015-07-29
IN2014DN06792A (instruction) 2015-05-22
US11247981B2 (en) 2022-02-15
US20200247779A1 (en) 2020-08-06
DK2804858T3 (da) 2020-03-16
US10526312B2 (en) 2020-01-07
KR20140116939A (ko) 2014-10-06
CA2861339A1 (en) 2013-07-25
ES2774267T3 (es) 2020-07-20
US10221160B2 (en) 2019-03-05

Similar Documents

Publication Publication Date Title
US11247981B2 (en) Metalloenzyme inhibitor compounds
CA2837400C (en) 5-(optionally substituted phenyl) pyridin-2-yl compounds as metalloenzyme inhibitors
CA2858681C (en) Metalloenzyme inhibitor compounds
CA2915054A1 (en) Metalloenzyme inhibitor compounds
HK1202872B (en) Metalloenzyme inhibitor compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180109